Sunday, March 30, 2008

A VIDEO OF HOPE........

A FRIEND SENT THIS TO ME-THANKS YVONNE
CHECK THE VIDEO OUT
MIKKO FROM FINLAND-A FRIEND
http://www.youtube.com/watch?v=210IHwqkdp8&feature=user

Saturday, March 29, 2008

ONE MORE-I FOUND THIS ON CLAUDI'S ALS BLOG

AND IT SUMS IT UP FOR ME TO ACCEPT THE LIFE CHOSEN FOR ME-BECAUSE SURE AS SHIT, I DID NOT PICK THIS LIFE. BUT IT IS WHAT IT IS-AND I CAN'T ACCEPT IT YET. I STILL WAKE UP EVERY MORNING THINKING I'M GOING TO BE CURED OF THIS F%#KING DISEASE. SEE, NOW I'M ANGRY SO WITH THAT SAID, HERE IS THE QUOTE:

"We must let go of the life we have planned, so as to accept the one that is waiting for us."

Friday, March 28, 2008

I know-I know. One more I PROMISE...........

I don't like that person - I better get to know them better.-- Jimmy Stewart
THIS IS ONE, BEFORE MY CHALLENGE, THAT I WOULD HAVE NEVER PRACTICED-BUT I DO NOW

it's late and i'm on a tangent

Strength does not come from physical capacity. It comes from an indomitable will.
Mahatma Gandhi

quote

there are no prizes given for suffering alone.
if someone wants to help you, accept it.
if you need help, ask for it.
if you lack joy, seek it.
do not try to hide from death or you will become invisable to life as well.

by joyce thompson, author

I am friends w/ this guy-he is Steve the architect in the video

IT'S INCREDIBLE WHAT HE HAS LOBBIED FOR AND WON!

IT'S A VERY HARD LOOK AT WHAT WE PALS ARE FACING. HE'S DOING A GREAT THING BUT I BROKE DOWN WATCHING THE VIDEO. IT'S NOT REALITY IT'S ACTUALITY.

http://www.youtube.com/watch?v=xFmgQLG9X_o

Most of you probably know that I have been working on two projects - one in MA and one in GA - to create a ALS group home that will support people on a vent. Not only support a vented person, but provide the kind of residential living environment that makes the decision to go on a vent a no-brainer.The MA project has a big head start in that I found people who shared my dream who were well on the way to making it happen. Barry Berman is an out-of-the-box nursing home director who realized that, as good as his facilities are, the needs of a younger, disabled person will NEVER be met in a traditional senior center. With enormous support from the MA-ALSA, this project is 80% financed, architectural plans near completion, land owned, permitted, and ready to break ground this year.There will be two ALS residences in an urban mid-rise condo building. Each house will have 10 private bedrooms, each with their own private bathroom, organized around a central living room and accessible kitchen. Each resident will have the option to cook for themselves or have a live-in chef cook-to-order. We are teaming with UMASS-Lowell engineering so that each resident will have a custom fit communication and mobility package created that will offer the latest technology (Eye-gaze, Tobii) so that the pALS can regulate the climate controls within the bedroom, open and close doors, call the elevator, select the desired floor, etc, all from the computer on their wheelchair. Each room will have a track hoist system that will provide access to 100% of the bedroom and bathroom. Oxygen will be piped into every room for those that need it. Most importantly, when necessary to go on a vent, you don't get kicked out. All 20 rooms will have vent support provided.It doesn't stop there. Upon exiting the elevator on the ground floor, residents will spill onto "Main Street", not a lobby. There will be coffee shops and cafés, courtyards and gardens, and transportation available upon request to go to downtown Boston, the Boston Common, or any other desired destination. Friends and family are encouraged to visit and will be welcome to stay over for a night or two or three...So far, the facility itself is paid for. There is another $5 million needed for the ALS upgrades. To this end, there is a major gifts campaign underway to cover these costs. The video linked below is to be used in this fund-raising effort. As you will see, I am honored to help in this endeavor by using my past experience as an architect to consult with the project architect to make sure our unique needs are uniquely addressed.Hope comes from many places. Never give in to fear because good things are happening all the time. I like something Barry says - our first goal is to get this residence built; our second goal is to not need it anymore and close it down.Massachusetts, almost done. Next up, Georgia.

Wednesday, March 26, 2008

Possible New Treatment Strategy For Muscular Dystrophy/ALS

Possible New Treatment Strategy For Muscular Dystrophy/ALS
Main Category: Muscular Dystrophy / ALS

Also Included In: Liver Disease / Hepatitis; Biology / Biochemistry; GeneticsArticle Date: 18 Mar 2008 - 2:00 PDT
An investigational antiviral drug currently undergoing human trials in Europe for treating Hepatitis C infections may have potential to reduce muscle cell damage in Duchenne and other forms of muscular dystrophy (MD). A research team led by Cincinnati Children's Hospital Medical Center reported their results using three different mouse models of MD in a letter posted online March 16 by the journal Nature Medicine. The investigational drug, Debio-025, is a known inhibitor of the protein cyclophilin D, which regulates the swelling of mitochondria in response to cellular injury. Researches decided to test the drug in mice engineered to carry MD after earlier laboratory tests showed deleting a gene that encodes cycolphilin D reduced swelling and reversed or prevented the disease's muscle-damaging characteristics. The mice were engineered as models of Duchenne muscular dystrophy and forms caused by a deficiency of two structural proteins, delta-sarcoglycan and laminin alpha2. "Similar to deleting the gene encoding cyclophilin D, we found that treatment with Debio-025 reduced mitochondrial swelling and necrotic manifestations in mice with muscular dystrophy. This is why we believe inhibiting cyclophilin D could be a new treatment strategy," said Jeff Molkentin, Ph.D., corresponding author of the study and a researcher in the Division of Molecular Cardiovascular Biology at Cincinnati Children's. "Debio-025 has already passed Phase II clinical trials in Europe and is considered safe in people, so we want to explore the possibility of conducting clinical trials in patients with Duchenne MD." During the onset of muscular dystrophy, the loss of certain proteins critical to muscle function - such as dystrophin - can lead to contraction-related micro-tears in muscle fibers and an influx of calcium around muscle tissue. When this happens, cyclophilin D is instructed to make the membranes of mitochondria more permeable. This causes mitochondria to be flooded by calcium and reorganize, swell and eventually rupture. This triggers cell death in muscle fibers and leads to the progressive muscle weakness, wasting and often early death associated with muscular dystrophy. Mice lacking the protein delta-sarcoglycan exhibited severe dystrophy and swelling in both skeletal and heart muscle. When Dr. Molkentin and his colleagues deleted the gene encoding cyclophilin D in these mice, the muscle cells returned to near normal and did not show appreciable signs of swelling and cell death. The investigators repeated the experiment with mice lacking a gene encoding laminin alpha2, which causes a more severe dystrophy, swollen skeletal muscle cells and premature death before the mice reach two months of age. In contrast, mice lacking both laminin alpha2 and cyclophilin D showed much healthier muscle cells, increased body weight and walked more. Also, 75 percent of the mice lacking laminin alpha2 and cyclophilin D lived more than three times longer than mice lacking only laminin alpha2. These findings led the research team to look for pharmacological treatments that also could inhibit cyclophilin D. The drug cyclosporine is a well-documented inhibitor of the protein, but its use is problematic because it also inhibits a protein, calcineurin, crucial to skeletal muscle cell repair after injury and to the development of skeletal muscle cells. The advantage of Debio-025 is that while it inhibits cyclophilin D and blocks cell death in a number of situations, the drug does not suppress the immune system or block calcineurin. The drug is manufactured by DebioPharm S.A. of Lausanne, Switzerland, which provided Debio-025 for use in the study. The researchers also found their study may have implications beyond skeletal muscle disease as cyclophilin D deletion reduced cardiac dysfunction caused by calcium-overload induced necrosis. This led the team to suggest that mitochondrial-dependent necrosis may also function as a common disease mechanism underlying a number of long-term degenerative disorders, something they plan to study in future research projects. Muscular dystrophies are inherited disorders that mostly affect striated muscle tissue and more commonly occur in boys. This disease results in progressive muscle weakness, wasting and in many instances death. There is no known cure for muscular dystrophy, although Cincinnati Children's is a recognized leader in disease-related research and a multi-disciplinary approach to patient treatment focused on maximizing ambulatory function and quality of life. ----------------------------Article adapted by Medical News Today from original press release.---------------------------- Also participating in the study were the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati; the Department of Anatomy and Cell Biology, University of Pennsylvania School of Dental Medicine, Philadelphia; DebioPharm S.A.; and the Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia. Members of the research team include Douglas P. Millay, Michelle A. Sargent, Hanna Osinska, Christopher P. Baines, Elisabeth R. Barton, Gre'goire Vuagniaux, H. Lee Sweeney and Jeffrey Robbins. Funding support was provided by National Institutes of Health, the Jain Foundation, the Fondation Leducq and the Paul Wellstone Muscular Dystrophy Cooperative Research Center of the National Institutes of Health. Cincinnati Children's Hospital Medical Center, one of the leading pediatric research institutions in the nation, is dedicated to changing the outcome for children throughout the world. Cincinnati Children's ranks second among all pediatric institutions in the United States in grants from the National Institutes of Health. It has an established tradition of research excellence, with discoveries including the Sabin oral polio vaccine, the surfactant preparation that saves the lives of thousands of premature infants each year, and a rotavirus vaccine that saves the lives of hundreds of thousands of infants around the world each year. Current strategic directions include the translation of basic laboratory research into the development of novel therapeutics for the treatment of disease, and furthering the development of personalized and predictive medicine. Additional information can be found at http://www.cincinnatichildrens.org/. Source: Nick MillerCincinnati Children's Hospital Medical Center

Sunday, March 23, 2008

Cloned cells treat Parkinson's in mice

Cloned cells treat Parkinson's in mice
By Maggie Fox, Health and Science EditorSun
Mar 23, 2:06 PM ET
Researchers who used cloned embryonic stem cells to treat Parkinson's disease in mice said on Sunday they worked better than other cells.
The researchers were trying to prove that it is possible to make embryonic stem cells using cloning technology and use them to provide a tailor-made treatment.
But they found that a mouse's own cloned stem cells were far less disruptive to its body than cloned cells taken from other mice.
"It demonstrated what we suspected all along -- that genetically matched tissue works better," said Viviane Tabar of Memorial Sloan-Kettering Institute in New York, who worked on the study.
"When you give the other type of tissue, non-autologous tissue, you get more inflammation than we anticipated. This is in a lab animal where we expect it to be tolerant. Normally when you do this in mice, you don't give matched cells," Tabar added in a telephone interview.
The mice given non-matched brain cells did more poorly than the mice given cells from their own clones, the researchers reported in the journal Nature Medicine.
Stem cells are the master cells of the body and embryonic stem cells are the ultimate master cells, giving rise to all the other cells and tissue. Cloning researchers hope one day to be able to take a little piece of skin and grow embryonic stem cells from it for personal, tailor-made medical treatments.
One disease always named that may benefit from this technology is Parkinson's. The incurable, fatal illness is caused by the destruction of specific brain cells.
THERAPEUTIC CLONING
It is sometimes treated with transplants of brain cells from cadavers or aborted fetuses. Stem cell researchers have argued that cloning technology might provide a better source of cells for treatment.
Tabar and his team first created a Parkinson's-like disease in mice using chemicals to destroy their brain cells.
They took ordinary cells from the tails of the mice, transferred the nuclei from them into hollowed-out mouse eggs cells, and made clones of the mice. This process is called somatic cell nuclear transfer, or "therapeutic cloning."
The cloned embryos were harvested for their stem cells after a few days. The researchers grew these in the lab and coaxed them into becoming the so-called dopaminergic brains cells that are lost in Parkinson's.
They put these into the brains of the injured mice. These mice got better, Tabar said.
No one has done this before. "It's incredibly hard and it involves a series of inefficient steps," Tabar said.
Several researchers have made cells that look and act like embryonic stem cells by reprogramming their genes. Tabar said her team would try using these so-called induced pluripotent stem cells in the same way.
Some people oppose using cloning technology to make human embryonic stem cells, or to creating human embryos for this purpose. It is also difficult to obtain human egg cells.
Scientists hope the induced pluripotent stem cells might provide a short cut that no one would object to.
"This is an exciting step down the pathway of creating a self-specific stem cell and getting away from the ethical demands of traditional embryonic stem cells," said Richard Boyd, Deputy Director of the Monash Immunology and Stem Cell Laboratories in Victoria, Australia.
(Edited by Alan Elsner)

Saturday, March 22, 2008

true.................

Life can only be understood backwards, but it must be lived forwards.- Soren Kierkegaard

Friday, March 21, 2008

ALS/LITHIUM UPDATE

HEY PEOPLE,

HOPE ALL IS WELL

IT'S BEEN 4 WEEKS ON LITHIUM AND I'M FEELING NO SIDE AFFECTS EXCEPT FOR MY EYES BURNING. THAT IS QUITE COMMON WITH THE PALS I'VE TALKED TO. MY DR. AT COLUMBIA SAID ABOUT 1 MONTH TO GET MY BLOOD LEVELS UP TO PAR-I GO TO COLUMBIA ON THE 25TH. PEOPLE I'VE TALKED TO THAT HAVE BEEN ON IT FOR OVER A MONTH HAVE REPORTED IMPROVEMENTS. AND THERE ALSFRS-R SCORE ARE THE SAME OR BETTER. THE ALSFRS-R SCORE IS HOW ALL OF US PALS ARE MEASURED. 48 BEING THE BEST 0 BEING THE WORST. I'M AT 42-- I WAS A 47 WHEN I GOT Dx IN SEPT 06'. IT WILL BE 2 YEARS IN JUNE THAT I FIRST NOTICED MY SPEECH WAS CONSISTENTLY WORSENING. THE DR. AT YALE GAVE ME 1.5 TO 2 YEARS TO LIVE IN JULY 07' AND I LAUGHED AT HIM AND TOLD HIM-NOT ME!! NO WAY I'M LEAVING THIS EARTH WITH OUT BEATING THIS F%$3ING DISEASE. AND LIKE I SAID BEFORE, I HAVE UNFINISHED BUSINESS W/ SOME OF YOU.

YOU CAN SEE WHAT THE QUESTIONS ARE ON THE ALSFRS-R TEST BY GOING TO: http://alslithium.atspace.com/alsfrs-r.html

HEY, I FOUND OUT ONE OF THE GUYS I KNOW FROM BACK IN THE DAY HAS ALS-HE IS 38. I EMAILED HIM-WE WERE LIKE HOLY SHIT. DECEMBER 06' WAS HIS Dx. MAN IT'S A SMALL WORLD. IT'S SO SAD WHEN YOU LOOK INTO THE FUTURE AND YOU SEE PEOPLE THAT ARE FURTHER ALONG IN THERE IN THE Dx. EVERYONE ENDS UP THE SAME WAY. AND WE PALS KNOW HOW THIS MOVIE ENDS. IT'S SCARY. BUT YOU HAVE TO LIVE IN THE DAY-RECENTLY MY FRIEND DAVE FROM MICHIGAN (A HUGE HOCKEY FAN AND PLAYER) SENT ME A BOOK AND A CD OF A PRIEST WHO HAS HAD ALS FOR 7 YEARS. HE PREACHES THAT THE FUTURE HOLDS NO GUARANTEES AND THAT WE SHOULD LIVE IN THE DAY. MAKES SENSE! THANKS DAVE.

LIVE- LAUGH AND HUG SOMEONE

quote someone sent me and it makes god damn sense

"I'm the one that has to die when it's time for me to die, so let me live my life, the way I want to." jimi hendrix.

Thursday, March 20, 2008

Being on the tightrope is living; everything else is waiting.

--Karl Wallenda

In walking a tightrope, a person has to learn to relax while going forward in a situation filled with risk. If he is tense and keeps his body rigid, he will lose his balance and fall. But if he stays relaxed and keeps his muscles loose while remaining very focused, he can continuously respond and readjust his balance while walking. Then he will experience the exhilaration of success

Video: Bee Venom Therapy Used to Treat ALS, PLS, MS, Arthritis

http://www.youtube.com/watch?v=6bJ-A1ABuTw --IT'S IN FRENCH BUT YOU WILL GET THE JIST
THIS IS A LINK FOR THE USE OF HONEY AS A SOURCE FOR HEALING A BUNCH OF DIFFERENT WOUNDS/DISEASE'S
http://www.worldwidewounds.com/2001/november/Molan/honey-as-topical-agent.html

A new treatment with bee venom therapy in Franc... (more)
Added: March 09, 2008
A new treatment with bee venom therapy in France, is used to reduce the development of the ALS and PLS disease but also arthritis. A new treatment with bee venom therapy in France, is used to reduce the development of the ALS and PLS disease but also , arthritis pain and MS (less)
Added: March 09, 2008

Tuesday, March 11, 2008

THIS IS GREAT-IT HAS A SUBLUMINAL MESSAGE THAT I HOPE YOU ALL WILL GET!!!

-You don’t have to be no billionaire to get a ticket up to the moon

-We all know somebody up there

-You need a helping hand, look I’m right here--to help you see clearly now

-To help you see clearly now

US Upholds 2 More Stem Cell Patents

good article

http://ap.google.com/article/ALeqM5gx0zqQ_DKfHcWkcNASNn89u0sc6gD8VBD96O0

US Upholds 2 More Stem Cell Patents
By RYAN J. FOLEY - 5 hours ago
MADISON, Wis. (AP) - The U.S. Patent and Trademark Office has upheld a second and a third University of Wisconsin-Madison patent covering embryonic stem cell research at the school.
In rulings made public Tuesday, Federal examiners confirmed two patents for scientist James Thomson's work on isolating embryonic stem cells of primates and humans. The patent office last month upheld another patent stemming from the work, but that ruling can be appealed.
Thomson in the 1990s became the first researcher to isolate the embryonic stem cells of primates and humans, which have great medical potential because they can turn into any type of cell in the body.
Two consumer groups and some scientists had said Thomson's work was obvious, given previous research on animals, and therefore ineligible to be patented. The examiners rejected that argument in the latest rulings, which cannot be appealed.
All three of the patents - issued in 1995, 1998 and 2001 - are held by the Wisconsin Alumni Research Foundation, a nonprofit that manages the university's patents.
The rulings mean the foundation will continue to control primary intellectual property rights to embryonic stem cell research in the United States. If that research leads to successful medical products or procedures before the patents expire in 2015, the school could win royalties.
The Foundation for Taxpayer and Consumer Rights and the Public Patent Foundation, which asked the patent office to throw out the patents in 2006, argued that their enforcement slowed U.S. stem cell research and drove some investment overseas.
The foundation agreed last year to waive some fees to encourage more industry-sponsored research and allow researchers to share their cells for free.
The foundation's stem cell affiliate has shipped cells to more than 560 researchers around the world since 1999. A vial of 6 million stem cells now costs about $500 for academic researchers.

Saturday, March 8, 2008

WE ARE ALL CONNECTED............

THE PLACES I HAVE RECEIVED HITS/EMAILS FROM HAVING MY BLOG-IT HAS BEEN INCREDIBLE-TO TOUCH SO MANY LIVES-IT MAKES IT ALMOST WORTH HAVING MY CHALLENGE (I WOULD RATHER NOT HAVE IT-BUT IT IS WHAT IT IS AND I'M EVER SO GRATEFUL). MY FRIENDS-PHIL & BARB AND MIKE, DONNA AND RYAN IN CANADA ARE ALWAYS IN TOUCH AND MY FRIEND FROM BRAZIL-HUMBERTO AND BORIS FROM MALDOVA AND CINZIA FROM ITALY. MIKE FROM ENGLAND AND MY FRIENDS FROM DOWN UNDER-MIKE & SHELAGH AND JODY & HAZEL. AND ALL OF YOU IN THE UNITED STATES-DAVE IN MICHIGAN AND ALL OF YOU IN STAMFORD, CT.

THANK YOU FROM MY HEART....

THIS IS ONLY IN THE PAST WEEK.......

2
Italy-San Severino Marche, Marche
4
United States-Fort Lauderdale, Florida
5
Australia-Brisbane, Queensland

34
Brazil-Aracaju, Sergipe

35 GermanyFreiburg, Baden-Wurttemberg
36
United States Jersey City, New Jersey
37
Canada Charlottetown, Prince Edward Island
38
South Africa-Pretoria, Gauteng
39
Poland-Warsaw, Warszawa
40
United States-Oshkosh, Wisconsin

26
United Kingdom-Leigh, Lancashire

8
Turkey-Zonguldak, Bolu
9
Canada-Taber, Alberta
10
United Kingdom-Ipswich, Suffolk
11
Canada-Courtenay, British Columbia

63
Australia-Hobart, Tasmania
64
United States-Wyoming, Michigan
65
United States-Norwalk, Connecticut
66
Canada-Kensington, Prince Edward Island
67
Lithuania-Vilnius, Vilniaus Apskritis
68
Canada-Georgetown, Ontario
69
United States-New York
70
United States-Stamford, Connecticut
71
United States-Fort Wayne, Indiana
72
Poland-Warsaw, Warszawa

81
Hungary-Vrpalota, Veszprem

41
Canada-Abbotsford, British Columbia
42
United States-Lawrence, Kansas
43
United States-Stamford, Connecticut
44
United States-Wyoming, Michigan
45
United States-spanola, New Mexico
46
United States-Chelmsford, Massachusetts
47
United States-Virginia Beach, Virginia
48
United States
49
United States-Kearny, New Jersey
50
United States-Savannah, Georgia
51
United States-Stamford, Connecticut
52
United States
53
Canada-Victoria, British Columbia
54
United States-Tunkhannock, Pennsylvania

LITHIUM/ALS UPDATE

HEY PEOPLE,


HOPE ALL IS WELL.


IT'S BEEN THREE WEEKS ON LITHIUM AND I'M FEELING NO SIDE AFFECTS EXCEPT FOR MY EYES BURNING. THAT IS QUITE COMMON WITH THE PALS I'VE TALKED TO. MY DR. AT COLUMBIA SAID ABOUT 1 MONTH TO GET MY BLOOD LEVELS UP TO PAR. PEOPLE I'VE TALKED TO THAT HAVE BEEN ON IT FOR OVER A MONTH HAVE REPORTED IMPROVEMENTS. AND THERE ALSFRS-R SCORE ARE THE SAME OR BETTER. THE ALSFRS-R SCORE IS HOW ALL OF US PALS ARE MEASURED. 48 BEING THE BEST 0 BEING THE WORST. I'M AT 42-- I WAS A 47 WHEN I GOT Dx IN SEPT 06'. IT WILL BE 2 YEARS IN JUNE THAT I FIRST NOTICED MY SPEECH WAS CONSISTENTLY WORSENING. THE DR. AT YALE GAVE ME 1.5-2 YEARS TO LIVE IN JULY 07' AND I LAUGHED AT HIM AND TOLD HIM-NOT ME!! NO WAY I'M LEAVING THIS EARTH WITH OUT BEATING THIS F%$3ING DISEASE. AND LIKE I SAID BEFORE, I HAVE UNFINISHED BUSINESS W/ SOME OF YOU.


YOU CAN SEE WHAT THE QUESTIONS ARE ON THE ALSFRS-R TEST BY GOING TO:

http://alslithium.atspace.com/alsfrs-r.html


HEY, I FOUND OUT ONE OF THE GUYS I KNOW FROM BACK IN THE DAY HAS ALS-HE IS 38. I EMAILED HIM-WE WERE LIKE HOLY SHIT. DECEMBER 06' WAS HIS Dx. MAN IT'S A SMALL WORLD. IT'S SO SAD WHEN YOU LOOK INTO THE FUTURE AND YOU SEE PEOPLE THAT ARE FURTHER ALONG IN THERE IN THE Dx. EVERYONE ENDS UP THE SAME WAY. AND WE PALS KNOW HOW THIS MOVIE ENDS. IT'S SCARY. BUT YOU HAVE TO LIVE IN THE DAY-RECENTLY MY FRIEND DAVE FROM MICHIGAN (A HUGE HOCKEY FAN AND PLAYER) SENT ME A BOOK AND CD OF A PRIEST WHO HAS HAD ALS FOR 7 YEARS. HE PREACHES THAT THE FUTURE HOLDS NO GUARANTEES AND THAT WE SHOULD LIVE IN THE DAY. MAKES SENSE! THANKS DAVE.

Tuesday, March 4, 2008

Brazil court to rule on stem cells


Brazil court to rule on stem cells
By STAN LEHMAN, Associated Press Writer2 hours, 7 minutes ago
Brazil's Supreme Court is set to decide if scientists in Latin America's largest country can conduct embryonic stem cell research, which many say can lead to cures for degenerative diseases such as Parkinson's and Alzheimer's.
The court's 11 justices are scheduled to rule Wednesday on a 2005 petition by then-Attorney General Claudio Fontelles, who argued that a new law allowing embryonic stem cell research was unconstitutional because it violates the right to life.
The law opened the way for research with embryos resulting from in-vitro fertilization that are frozen for at least three years.
"Brazil has the potential to be a significant leader in this field," said Bernard Siegel, the executive director of the Florida-based Genetic Policy Institute. "And if the Supreme Court decides to allow this kind of research, then Brazil will become the Latin American leader in this field."
He said Brazilian scientists have done "pathfinding" work with adult stem cells for the treatment of cardiovascular diseases and Type 1 diabetes. If given the green light to use embryonic stem cells, "then there is no reason why they won't be able to make important breakthroughs," he added.
Roman Catholic Church officials have urged the court to ban such research because the process results in the destruction of embryos, which it and other groups say ends human life.
"Our position is not against science," Archbishop Geraldo Lyrio Rocha, president of the National Conference of Brazilian Bishops, said last week. "It is in favor of life."
He noted that the church supports adult stem cell research, which he described as "ethically acceptable."
Adult stem cells, which are harvested without destroying an embryo, can be used to recuperate damaged tissue. But scientists say they are less flexible than embryonic stem cells, which can develop into different types of cells.
"Adult stem cells are excellent and have generated a lot of valuable knowledge," said Mayana Katz, a University of Sao Paulo geneticist. "But embryonic stem cells are more powerful and offer many more possibilities to find cures for diseases like Parkinson's and Alzheimer's."
She said that while embryonic stem cell research is legal, scientists have put most projects on the back burner pending the Supreme Court's ruling.
"We want the chance of conducting the kind of research being done in developed countries like Great Britain, Sweden, Japan and Israel," she added.
Meanwhile, a January survey conducted by the Public Opinion Research Institute, or Ibope, shows that 95 percent of those interviewed favor embryonic stem cell research.
___
Associated Press writer Marco Sibaja contributed to this report from Brasilia.

Monday, March 3, 2008

A FELLOW MEMBER OF THE ORDER OF MALTA SENT ME THIS

YOU SAY- -GOD SAYS
BIBLE VERSES
'It's impossible'
All things are possible
Luke 18:27
'I'm too tired'
I will give you rest
Matthew 11:28-30
'Nobody really loves me'
I love you
John 3:1 6 & John 3:34
'I can't go on'
My grace is sufficient
II Corinthians 12:9 , Psalm 91:15
'I can't figure things out'
I will direct your steps
Proverbs 3:5- 6
'I can't do it'
You can do all things
Philippians 4:13
'I'm not able'
I am able
II Corinthians 9:8
'It's not worth it'
It will be worth it
Roman 8:28
'I can't forgive myself'
I Forgive you
I John 1:9 & Romans 8:1
'I can't manage'
I will supply all your needs
Philippians 4:19
'I'm afraid'
I have not given you a spirit of fear
II Timothy 1:7
'I'm always worried and frustrated'
Cast all your cares on ME
I Peter 5:7
'I'm not smart enough'
I give you wisdom
I Corinthians 1:30
'I feel all alone'
I will never leave you or forsake you
Hebrews 13:5

Saturday, March 1, 2008

AN ANONYMOUS COMMENTOR SENT ME THIS

IT'S A GREAT READ....
The story is on Patty Izzo. A 12 year old diagnosed with ALS in 1999. "ALS Research Paper"
(347 KB)Denise Kurowski wrote this research paper to raise ALS awareness at her school Friend of ALS patient
http://www.lesturnerals.org/pdf/Denise%20Kurowski.pdf

Friday, February 29, 2008

CHECK THIS PICTURE OUT


KIND OF WEIRD HUH? I'M EATING A PB&J AND IT WAS BEFORE A SHOWER-HENCE THE SCRUBBY LOOK!!!!!!!!
PEOPLE THINK IT IS A SIGN?
TAKE CARE,
DREW

Gene breakthrough for motor neurone disease

THIS IS THE INTERVIEW TRANSCRIPT

AM - Gene breakthrough for motor neurone disease [This is the print version of story http://www.abc.net.au/am/content/2008/s2175916.htm]
AM - Friday, 29 February , 2008 08:00:00
Reporter: Sophie Scott
PETER CAVE: Australian scientists have made an important discovery about what causes the devastating illness, motor neurone disease. They have found it's an abnormal gene which kills the nerves from the brain to all the muscles in the body.National medical reporter, Sophie Scott, is speaking to Professor Garth Nicholson from the ANZAC Research Institute.
GARTH NICHOLSON: Some years ago, it was found that a particular protein was present in large amounts in the spinal cords of people dying from motor neurone disease and associated dementia, which is often occurring with motor neurone disease. This protein is called TDP43. So, we looked at TDP43 in families with motor neurone disease to see if it could cause motor neurone disease running in families, because we didn't know whether the protein found in the spinal cord was trying to help the body recover from the disease or was actually poisoning the body. And so this was the smoke, it had something to do with motor neurone disease, and we've actually found a fire, because we have proven in the families that have motor neurone disease with a mutation in this gene, this is causative, it causes motor neurone disease.
SOPHIE SCOTT: So, how important is that, given that we haven't really known what causes this disease up until now?
GARTH NICHOLSON: This … many people have thought for years that motor neurone disease might be some poison of some sort in the environment. But here we've been able to show that it seems to be a poison in the body itself, something's going wrong so the mechanism actually becomes dangerous and leads to the death of the neurones.
SOPHIE SCOTT: What are the implications of that for things like prevention or treatment?GARTH NICHOLSON: Yes, if we're right and this is indeed the protein that's causing damage in the majority of patients with motor neurone diseases, so opens up the chance of trying to reduce this protein or get rid of it, or prevent it. And then you'd have either a prevention or a cure for the disease.
SOPHIE SCOTT: At the moment, what's the situation with either treating patients with motor neurone or offering them some hope?
GARTH NICHOLSON: Motor neurone disease is probably many diseases, and some varieties are extremely lethal, killing people in three months, and some varieties go for years and years, you know, it doesn't really kill people. So, there's a big variation in motor neurone disease and this may reflect all different varieties of motor neurone disease with different mechanisms. But if there's an underlying mechanism that's common to all, then you've got a chance of a treatment. And because this protein is generally … is found in all motor neurone disease, this does offer some hope that we might find a general treatment for all.
PETER CAVE: Professor Garth Nicholson, ending that report from our national medical reporter, Sophie Scott.

Aussie researchers discover cause of motor neurone disease

ANOTHER GREAT ARTICLE-HOPE IS ALL WE ARE ASKING FOR
Aussie researchers discover cause of motor neurone disease
By medical reporter Sophie Scott
Posted Fri Feb 29, 2008 7:00am AEDT Updated Fri Feb 29, 2008 9:19am AEDT
Audio: Scientists find motor neurone disease gene (AM)
Australian scientists have discovered the cause of motor neurone disease.
Scientists at Sydney's ANZAC Research Institute have been studying patients with the disease for the last 10 years.
They have found that patients with the debilitating illness have an abnormal protein that causes the fatal illness.
Lead scientist Professor Garth Nicholson says the findings open the way for new treatments.
"The proof of it is that we found patients who have this abnormality with the disease in families and people who didn't get the disease didn't have this abnormality," he said.
Professor Nicholson says the gene causes a poison that destroys motor neurones.
"Many people have thought for many years that motor neurone disease might be a poison of some sort, in the environment," he said.
"But here we have been able to show that it seems to be a poison in the body itself - something is going wrong and leads to the death of the neurones."
The findings have been published in the journal Science.
EDITOR'S NOTE: This article originally incorrectly stated the cause of motor neurone disease was a gene. It is in fact a protein

Motor neuron disease breakthrough

GREAT NEWS..........
Motor neuron disease breakthrough

http://www.telegraph.co.uk/earth/main.jhtml?view=DETAILS&grid=&xml=/earth/2008/02/28/scineron128.xml

By Roger Highfield, Science Editor
Last Updated: 7:01pm GMT 28/02/2008
A breakthrough in understanding motor neuron disease, the incurable degenerative disorder, has been made by scientists.
The world's best known scientist, Prof Stephen Hawking, is a sufferer of the devastating disorder. Now an international effort led by King's College London reports in the journal Science that it has identified a rare mutation associated with some cases that they believe reveals the underlying mechanism that causes the disease for the first time, a key step towards developing effective treatments.
Deposits of an abnormal protein now appear central to the processes that trigger the dying neurons characteristic of the disease, also called amyotrophic lateral sclerosis (ALS), linking it to other ones marked by abnormal proteins, notably Parkinson's, variant CJD and Alzheimer's disease.

To make the find, Prof Chris Shaw, Jemeen Sreedharan and colleagues in the United Kingdom and Australia analysed a large British family with the inherited form of the disease. They found mutations in a gene called TDP-43 that can directly cause the disease.
Clumps of the TDP-43 protein accumulate within dying motor neurons. This discovery indicates that TDP-43 accumulation is not just a by product of nerve degeneration - as some had thought - but may be a critical event that is central to the disease process.
At the moment, doctors do not know the cause of over 95 per cent of cases of the disease, though they do know that genetic factors play an important role. Because drugs based on the only other gene linked to the disease, called SOD, had failed to have any beneficial effect in patients scientists had been searching for a new clue to the cause.
TDP-43 is depositied in 95 per cent of patients and although TDP-43 gene mutations are rare they do give us a potentially powerful biological tool. "If we can use the mutant human gene to generate cellular and animal models of MND we have a real chance of understanding how motor neurons degenerate. This could dramatically accelerate the drug screening process", says Prof Shaw.
Prof Shaw said the find opens "fantastic opportunities" and is now going to create human stem cells containing the mutation with Sir Ian Wilmut of Edinburgh University, which will be an invaluable tool to simulate, understand and test treatments for the devastating disease.
The disease attacks the upper and lower "motor neurons", causing weakness and wasting of muscles, increasing loss of mobility in the limbs and difficulties with speech, swallowing and breathing. It can affect any adult at any age but most people diagnosed with the disease are over the age of 40, with the highest incidence occurring between the ages of 50 and 70.
The incidence or number of people who will develop the disease each year is about two people in every 100,000. The prevalence or number of people living with MND at any one time is approximately seven in every 100,000.
Brian Dickie, director of research development at the MND Association, which partly funded the study, said: "The discovery of a new cause of the disease is of international importance, allowing researchers around the world to rapidly generate more pieces of the complex puzzle that is MND.
"This new information will be a spring board to greater understanding of the processes that cause motor nerves to die - and it is through such understanding that we will develop the treatment strategies to defeat this devastating disease."
Information appearing on telegraph.co.uk is the copyright of Telegraph Media Group Limited and must not be reproduced in any medium without licence. For the full copyright statement see Copyright

Wednesday, February 27, 2008

Thought for today

'When You're Down to Nothing, God is up to Something'

'Worry looks around, Sorry looks back, Faith looks up.

Tuesday, February 26, 2008

UPDATE TO THE ITALIAN STUDY

Italian ALS study
(48 patients, after 15 months)
32 TAKING RILUZOLE: 30 percent mortality, disease progressed 50 percent.
16 TAKING RILUZOLE & LITHIUM: 2 deaths-one by heart attack and one had advanced bulbar at the start of the study, 14 others w/ no measurable progression.
Source: Francesco Fornai, University of Pisa

THEY ARE DOING A STUDY WITH A 100 PALS. AND IN THE USA THEY ARE STARTING A CLINICAL TRIAL AT JHU. I'M ON LITHIUM SINCE THURSDAY WITH NO SIDE AFFECTS. IT WILL TAKE ONE MONTH TO FULLY INFILTRATE MY BLOOD.

EXCITED DOESN'T EXPLAIN MY EMOTIONS RIGHT NOW. IT'S MORE GRAND THAN EXCITED-IT IS HOPE! SOMETHING WE PALS LIVE FOR..............

Monday, February 25, 2008

WEBSITE FOR ALS, MS AND PARKINSON'S DISEASE AND OTHERS

THIS IS BY FAR THE MOST COMPREHENSIVE WEBSITE FOR PEOPLE WHO HAVE MND, ALS, MS OR PD. THE DEPTH THIS WEBSITE HAS GOES DEEPER INTO THE DAILY LIVES OF THOSE LIVING W/ THESE DISEASE'S. A MUST SEE................... WWW.PATIENTSLIKEME.COM

About PatientsLikeMe
Founded in 2004 by three MIT engineers whose collective experience spans from running the world's only non-profit biotechnology laboratory to large-scale online commerce applications, PatientsLikeMe is a privately funded company dedicated to making a difference in the lives of patients diagnosed with life-changing diseases. Our personal experiences with ALS (Lou Gehrig's disease) inspired us to create a community of patients, doctors, and organizations that inspires, informs, and empowers individuals. We're committed to providing patients with access to the tools, information, and experiences that they need to take control of their disease.
In 1998, a young carpenter named Stephen Heywood was diagnosed with ALS. The Heywood family began taking charge of Stephen's care, searching the world over for ideas that would extend his life and improve the way he lived. This set in motion a series of events that have led to PatientsLikeMe, a new system of medicine by patients for patients. We're here to give patients the power to control their disease and to share what they learn with others. We're here to help you.
Our goal is to enable people to share information that can improve the lives of patients diagnosed with life-changing diseases. To make this happen, we've created a platform for collecting and sharing real world, outcome-based patient data (patientslikeme.com) and are establishing data-sharing partnerships with doctors, pharmaceutical and medical device companies, research organizations, and non-profits. Contact us if you're interested in working together to achieve our goals.

Saturday, February 23, 2008

MAP

I'VE BEEN ASKED QUITE A FEW OF QUESTIONS AS TO WHERE SHENYANG, CHINA IS LOCATED--LOOK ABOVE BEIJING AND TO THE EAST-IT IS ABOUT 300 MILES NORTHEAST OF BEIJING.
HOPE ALL IS WELL.
DREW

Exciting New Human ALS Trial: Lithium and Riluzole

FROM THE DIRECTOR

Exciting New Human ALS Trial: Lithium and Riluzole
Recently, a study was published in the Proceedings of the National Academy of Science, by an Italian group of scientists and clinicians examining the ability of lithium to increase the neuroprotective actions of riluzole in ALS mice and patients.
This study was highly significant in that it showed, for the first time, a marked potentiation of the actions of riluzole in ALS patients. It showed that riluzole and lithium - combined - were far more effective than riluzole alone at increasing survival and slowing disease in ALS patients.
Although riluzole has been shown in multiple, large, independent human trials to be effective in ALS, its actions to slow disease are quite small. Lithium, a salt, has many, many actions in the nervous system but is best known for its ability to treat a very different brain disease: manic depression.
The combination of both lithium and riluzole in ALS patients appeared to keep patient alive longer and slow loss of breathing capacity and other clinical measures of disease progression.
To those of us who work very hard to translate science into effective therapeutics and to those who diagnose and manage ALS patients, this new study is extremely exciting.
It shows that drug combinations, when studied carefully, might actually very significantly slow down ALS and extend the lives of patients.
The actual study by the Italians was quite small. And the history of most modern medical research has taught us that small studies with patients need to be replicated with larger studies. All too often results of small studies are not reproduced when better and larger studies are carried out.
For this reason Packard Center clinicians and scientists are in the process of working with major ALS non-profits, the government, and European colleagues to move as quickly as possible to replicate this very small study with a larger one.
Details of the study will be reported as soon as we know more.
Does that mean patients should wait until a larger study of lithium and riluzole is complete before they consider taking the drug? Lithium is a drug very widely used for psychiatric disorders like manic depression. Its use must be monitored by physicians with appropriate physical exams and blood tests.
All patients interested in taking lithium plus riluzole should discuss this with their local physicians and/or neurologists.
The community of scientists and patients have all too often been disappointed with outcomes of ALS clinical trials, especially after we all get excited by experimental mouse data. But human trials provide the only data that really count
.
We deeply hope that this novel combination of riluzole and lithium will turn out to be the “real thing” and we are collectively working hard to make that happen.

Jeffrey D. Rothstein MD, PhD

Professor of Neurology and Neuroscience Director,

Robert Packard Center for ALS Research

STEM CELLS-GERMANY

Germany considers changing stem cell laws
By Madeline ChambersThu Feb 14, 11:36 AM ET
German lawmakers are considering changes to laws on stem cell research as pressure grows for an easing of restrictions that local scientists complain prevent them from keeping up with global advances.
The Bundestag lower house of parliament devoted nearly four hours on Thursday to the divisive issue -- a sensitive subject in Germany due to Nazi genetic experiments linked to creating a "master race." A vote is set to take place in mid-March.
In 2002, parliament banned the production of embryonic cells from pre-existing stem cell lines. To ensure foreign laboratories did not produce cell lines for the German market, it also barred German scientists from working on any lines created after January 1, 2002.
German laws are tighter than in some other European countries, including Britain and Sweden, and researchers have expressed frustration that they cannot take part in international projects using lines created after 2002.
"You have to take account of the fact that researchers need qualitatively better cells," Technology Minister Annette Schavan told German television shortly before the debate, adding she wanted to ensure German scientists could keep up globally.
A range of options are on the table -- from tightening the rules and banning all imports of stem cells to lifting the ban altogether. Leaving the law as it is also possible.
A proposal to introduce a more recent cut-off date, probably May 2007, for the import of stem cell lines has won most support from lawmakers so far.
Many legislators have yet to decide and the main parties are not promoting specific positions on the issue.
Thursday's parliamentary debate reflected the deep divisions in Germany which has roughly equal numbers of Catholics, who oppose stem cell research, and Protestants.
"There is no argument for killing human life for science," said Hubert Hueppe, a member of Chancellor Angela Merkel's Christian Democrats (CDU) who wants to tighten the rules.
Some opponents of change argued the medicinal value of stem cell research had to be proven.
"The desire to heal serious diseases through embryonic stem cell research is only a wish," said Greens lawmaker Priska Hinz.
Scientists say stem cells offer the potential to treat conditions such as diabetes and Parkinson's' disease and to regenerate damaged organs.
However, scientific advances are also likely to affect the ethical debate in future. Some researchers are using cloning technology to try to make stem cells and late last year scientists said they had found a way to make stem cells from ordinary skin cells.
(Editing by Matthew Jones)

Friday, February 22, 2008

A VIDEO ON LIVING BY SOMEONE THAT IS DYING

MY PHYSICAL THERAPIST SENT ME THIS. RULES TO LIVE BY--- JUST WATCH IT!!
Take the time to watch, and listen and learn...
http://video.stumbleupon.com/#p=ithct48cqw
SOME THINGS I TOOK FROM THIS:
Brick walls are there for a reason---they are there to show us how bad we really want things

Don’t complain: just work harder

Tuesday, February 19, 2008

MY CONVERSATION W/ MY EGO

AN UPDATE:

I'M DOING WELL. I WALKED OUT OF GAYLORD THURSDAY WITH A WALKER BUT HAVE NOT USED IT SINCE. IT'S LIKE GOING TO THE DENTIST-YOU NEVER WANT TO GO BUT YOU KNOW YOU HAVE TO. THAT IS WHERE I'M AT RIGHT NOW. I KNOW I HAVE TO BUT I DON'T WANT TO GO THERE. IT'S AN EGO THING-I'M SORRY BUT IT IS. I HAVE AN ARGUMENT W/ MY EGO EVERY MORNING AND IT GOES SOMETHING LIKE THIS:

MY BRAIN-

"YOU KNOW IT'S THE SAFE WAY TO WALK"

MY EGO-

"SHUT UP, YOUR GIVING IN"

MY BRAIN-

"NO, IT'S WHAT'S BEST FOR YOU"

MY EGO-

"YOU'RE WEAK-I'M SHUTTING DOWN YOUR ABILITY TO REASON W/ ME"

MY BRAIN-

"NO, WAIT"

MY EGO-

"I CAN'T HEAR YOU"

AND THEN THE CONVERSATION FALLS ON DEAF EARS. SO THAT'S WHERE I'M AT. I HAVE NOT BROKEN DOWN ABOUT MY DISEASE BUT 2 TIMES. AND WHEN I DECIDED TO START A BLOG-I WANTED TO PUT IT ALL OUT THERE. I THINK I'VE CONVEYED A MESSAGE THAT IT'S OKAY TO PUT YOURSELF OUT THERE AND SHARE YOUR LIFE. WELL, I BROKE DOWN YESTERDAY. PEOPLE THAT WERE W/ ME SAID TO LET IT ALL OUT. SO I DID-AND IT FELT GOOD. A GOOD CRY IS GREAT.

AND SO THE JOURNEY GOES FORWARD. I START THE LITHIUM TOMORROW............................!!!!!!!!!!!

THANK YOU AGAIN FOR ALL THE SUPPORT-KEEP IT COMING.

DREW

Saturday, February 16, 2008

PLEASE PRAY FOR HER

MY FRIEND MIKEY FROM CHINA SENT ME THIS. HALEY NEEDS OURS PRAYERS-THANK YOU
I don't send out a MASS E-Mail like this very often. But I know this one is real because I saw the eyes of the person telling me about it. When I was in my Stastics class this morning, I was told by one of the other students that he had to go back to the hospital. When I inquired about it, he told me all about Haley. I could see the fear in his eyes, and he was fighting to stay tough. I promised him that I would pray for her, and tell as many people that I could to do the same. I can't pretend to know why something like this happens, and it sure is hard to see God in it. BUT, that is one of the simple beauties of God's great plan. We aren't suppose to understand it, or even agree with it. It would probably be our plan then, and we all know that would be totally messed up. So please, take a minute to read over this WEB-PAGE started for Haley, and just pray for her. Then, send this out to as many people as you can. I know the healing power of PRAYER through God, I have seen his touch affect my life in so many ways. This is so important to me.

So please at the very least take a minute to appreciate your loved ones. Life is so fragile, and short. PRAY FOR HALEY! ASK GOD TO STRENGTHEN HER FAMILY!--

God bless, Mikey

Friday, February 15, 2008

Thursday, February 14, 2008

RESULTS OF THE LITHIUM STUDY

THIS IS THE CLINICAL STUDY DONE IN ITALY W/ LITHIUM:


Lithium delays progression of amyotrophic lateral sclerosis
Francesco Fornai*†‡, Patrizia Longone§, Luisa Cafaro†, Olga Kastsiuchenka*, Michela Ferrucci*, Maria Laura Manca¶,Gloria Lazzeri*, Alida Spalloni§, Natascia Bellio, Paola Lenzi*, Nicola Modugno†, Gabriele Siciliano¶, Ciro Isidoro,Luigi Murri¶, Stefano Ruggieri†, and Antonio Paparelli*

*Department of Human Morphology and Applied Biology, and ¶Department of Neuroscience, Clinical Neurology, University of Pisa 56100 Pisa, Italy;
†Istituto Neurologico Mediterraneo, Istituto Di Ricovero e Cura a Carattere Scientifico Neuromed, 86077 Pozzilli (IS), Italy; §Molecular Neurobiology Unit,
Santa Lucia Foundation, 00179 Rome, Italy; and Department of Medical Sciences, University of Novara, 28100 Novara, Italy


Edited by Thomas C. Su¨ dhof, University of Texas Southwestern Medical Center, Dallas, TX, and approved December 21, 2007 (received for review
August 24, 2007)


ALS is a devastating neurodegenerative disorder with no effective
treatment. In the present study, we found that daily doses of
lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter,
delay disease progression in human patients affected by ALS. None
of the patients treated with lithium died during the 15 months of
the follow-up, and disease progression was markedly attenuated
when compared with age-, disease duration-, and sex-matched
control patients treated with riluzole for the same amount of time.
In a parallel study on a genetic ALS animal model, the G93A mouse,
we found a marked neuroprotection by lithium, which delayed
disease onset and duration and augmented the life span. These
effects were concomitant with activation of autophagy and an
increase in the number of the mitochondria in motor neurons and
suppressed reactive astrogliosis. Again, lithium reduced the slow
necrosis characterized by mitochondrial vacuolization and increased
the number of neurons counted in lamina VII that were
severely affected in saline-treated G93A mice. After lithium administration
in G93A mice, the number of these neurons was
higher even when compared with saline-treated WT. All these
mechanisms may contribute to the effects of lithium, and these
results offer a promising perspective for the treatment of human
patients affected by ALS.


autophagy clinical study G93A mice morphological analysis
ALS is a devastating neurodegenerative disorder with no
effective treatment that usually leads to death within 3–5
years from diagnosis (11 months for the bulbar form) (1). ALS
occurrence is primarily (90%) sporadic, while only 10% is
familial (fALS). Approximately 20% of fALS are due to mutations
of the gene coding for the enzyme copper–zinc superoxidedysmutase
(SOD1) (2). Transgenic mice over expressing the
human mutant SOD1 develop a pathology that is very similar to
that seen in ALS patients [see supporting information (SI) Text
for a comparison]. Studies in animal models or in vitro led to the
identification of a variety of alterations in ALS motor neurons
(MN) (1, 3, 4); however, other cells in the spinal cord besidesMN
are affected (5–8). For instance, a class of interneurons die
either before or concomitantly with MN, as found in mice (9, 10)
and postulated in humans for Renshaw-like cells (11). Again,
glial cells participate in the deleterious interplay leading to MN
degeneration (6–8).
After the generation of the SOD1 ALS mouse models,
attempts have been made to find effective treatments. However,
so far, none of these trials has led to effective clinical outcomes.
Lithium is a compound used as a mood stabilizer, which is
neuroprotective in a variety of disease models (12, 13), such as
brain ischemia (14) and kainate toxicity (15). The ability of
lithium to promote autophagy, through the inhibition of the
inositol-monophosphatase 1 (16–18), together with the protective
effects of autophagy in neurodegeneration (19–22),
prompted us to test the neuroprotective effects of lithium in the
G93A ALS mouse model. Based on the promising data, we
obtained in mice we quickly moved into a clinical trial, which is
now at the end of its second year.
Results
Effects of Lithium on Disease Duration and Survival in G93A Mice.
G93A male mice were treated daily with lithium carbonate (1
mEq/kg, i.p.), starting at 75 days of age. Lithium treatment
prolonged the mean survival time from 110.8 5.0 days (n20)
to 148  4.3 (n 20, 36% of the life span of these mice; Fig.
1a; P  0.001) and, most importantly, increased disease duration
(from a mean of 9 days to 38 days, 300%; Fig. 1b; P  0.05)
compared with the G93A mice treated with saline. Even when
lithium treatment was started at the onset of motor symptoms,
the increase in disease duration was still comparable (data not
shown). More specifically, lithium delayed the onset of paralysis
and limb adduction (Fig. 1c) and significantly improved additional
tests we report in SI Fig. 6, such as rotarod, grip strength,
and stride length.
Effects of Lithium Treatment on Motor Neuron Survival (Lamina IX of
Lumbar and Cervical Spinal Cord and Brainstem Motor Nuclei). These
effects were accompanied by a reduced loss of lumbar MN at 90
days of age (SI Fig. 7). However, at the end of disease (which
occurred later following lithium), the number of alpha-MN
within lumbar lamina IX of the G93A mice treated with lithium
was comparable to that found in the saline-treated mice that had
died previously (SI Fig. 8). However, even at this stage, we
detected a disease modifying effect of lithium. This consisted of
(i) preservation of the size of MN (SI Fig. 8 d and e); (ii)
preservation of MN number and size in those areas [i.e., cervical
spinal cord (SI Fig. 9) or the nucleus ambiguous (SI Fig. 10)],
which degenerate later compared with lumbar lamina IX (23,
24); (iii) decreased astrocytosis (SI Fig. 11); and (iv) decreased
alpha-synuclein, ubiquitin, and SOD1 aggregation (see SI Fig. 6
and Discussion in SI Text).
Effects of Lithium Treatment on the Renshaw-Like Cell Area (Lamina
VII). Lamina VII contains a larger number of interneurons,
defined as Renshaw cells, which form a collateral circuit that
Author contributions: F.F., P. Longone, C.I., L.M., S.R., and A.P. designed research; O.K.,
M.F., M.L.M., G.L., A.S., N.B., P. Lenzi, N.M., and G.S. performed research; L.C., M.F., M.L.M.,
G.L., P. Lenzi, G.S., C.I., L.M., S.R., and A.P. analyzed data; and F.F. and P. Longone wrote the
paper.
The authors declare no conflict of interest.

This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
‡To whom correspondence should be addressed. E-mail: f.fornai@med.unipi.it.
This article contains supporting information online at www.pnas.org/cgi/content/full/
0708022105/DC1.
© 2008 by The National Academy of Sciences of the USA
2052–2057 PNAS February 12, 2008 vol. 105 no. 6 www.pnas.orgcgidoi10.1073pnas.0708022105

INTERESTING

The butterfly silently returns when the winds blow free.

Wednesday, February 13, 2008

Stem cell scientists explore options
By Yevgeniy Sverdlik, CORRESPONDENT
Article Created: 02/13/2008 02:41:12 AM PST

SAN RAFAEL — Stem cell research offers the promise of finding cures for some of the most feared and intractable diseases known to man.
A panel of biologists made that case over the weekend to an audience of Bay Area university students, other scientists and members of the community.
Stanford University's Renee A. Reijo Pera, director of the Center for Human Embryonic Stem Cell Research and Education, emphasized the importance of learning more about embryonic development at its earliest stages to realize the therapeutic potential of stem cells.
"It's important that we begin to really understand human development and how cell fate is determined," Pera said. "It's the essence of human embryonic stem cell biology."
Although scientists have learned how to create human embryonic stem cell lines, Pera said, they have yet to learn how to direct those stem cells to morph into specific types of cells that are needed to cure some of the diseases the technology promises to cure.
"Can we direct the fate of the cells?" Pera said. "In most cases, the answer is 'No, we can't do it exactly right.' But we actually are getting a lot closer."
The keynote speech was delivered by Gilberto R. Sambrano, head of the Training Grant Program at the California Institute for Regenerative Medicine. The institute was created in 2004 as a result of state Proposition 71, which charged it with distributing $3 billion of state money for stem cell research.
One of the institute's goals is to develop tangible proof of the principle that transplanted cells derived from stem cells can be used to restore function for at least one disease, Sambrano said.
To address the uncertainty of this relatively new area in science and the amount of money being spent on it, Sambrano pointed to the optimistic mind-set scientists have about it.
"Like any research conducted, it is research and it is a question," Sambrano said. "Do we want to explore it or not, and if we don't explore it, what do we miss out? I guess, until we get there, we don't know. But I think that the potential for it as an enabling technology has excited scientists like nothing has in recent times."
Mary Khan of San Anselmo came to the conference, which was held at Dominican University of California in San Rafael, to learn how far stem cell research has come. Khan's husband suffers from kidney failure.
"My husband is a dialysis patient," Khan said, "and I am trying to research what I think is the only way someone can benefit and ever possibly get help for kidneys, which is to basically to re-grow and re-generate your kidney."
THERE IS ALWAYS HOPE

Tuesday, February 12, 2008

Human stem cell tests could be near

Human stem cell tests could be near
Geron CEO plans embryonic stem cell tests in humans this spring if the biotech meets the FDA's 'high bar
.'
By Aaron Smith
February 12 2008: 9:07 AM EST

NEW YORK -- The first experiments using human embryonic stem cells in human subjects could begin within a few months, the chief executive of biotech Geron said Monday.
At the annual BIO CEO conference in New York, Dr. Thomas Okarma said Geron plans to start embryonic stem-cell studies in humans with spinal cord injuries toward the end of the second quarter. Okarma said the tests would involve up to 40 human patients, while all prior tests involved rats.
This assumes that the Food and Drug Administration gives Geron a green light to proceed with the human test. Okarma said the FDA will set a "high bar" in regulating this new type of science.
Ren Benjamin, analyst for Rodman & Renshaw, believes the regulatory process could be time-consuming, because it's unprecedented.
"This is the first time that a human embryonic stem cell application is being submitted to the FDA, so there's a good chance that some questions will arise," he said.
Geron (GERN), based in Menlo Park, Calif., is also in early-stage studies with stem cell-based drugs for diabetes and heart failure. All of these experimental treatments are years away from potentially entering the market.
Advanced Cell Technology Inc. and Novocell Inc. also use human embryonic stem cells, but Geron is the only one of the these companies that's traded on the Nasdaq. Advanced Cell plans to begin testing in humans this year, but Novocell is further behind.
Cytori Therapeutics (CYTX) and Osiris Therapeutics (OSIR) use stem cells taken from adult human tissue, which insulates from the controversy surrounding the use of human embryonic stem cells, which are obtained through in vitro fertilization.
Human-based embryonic stem cells are prized by researchers for their ability to regenerate quickly and morph into different types of cells. Supporters believe their use could someday help people with spinal injuries walk again or cure patients with degenerative diseases like Alzheimer's and Parkinson's.
But the pro-life contingent, including President Bush, opposes using human-derived stem cells, on the grounds that it creates embryos only to destroy them. Supporters of the science dispute that notion, saying that the blastocysts used as stem cell sources would be thrown out as medical waste if they weren't used in research.
In 2001, President Bush limited federal funding for human-derived stem cells to only those lines that existed at the time. In 2007, he vetoed a Congressional bill to lift those restrictions.
But in November, scientists unveiled a new type of experimental technology on Nov. 21 that sent Geron's stock into a volatile tailspin. Research teams from the University of Wisconsin in Madison and the University of Kyoto in Japan separately announced that they'd "reprogrammed" adult cells to act like embryonic stem cells.
Geron's stock has fallen more than 40 percent since then, though Okarma shrugged off the potential threat of reprogramming because it's still in the infantile stages.
"The natural human embryonic stem cell is the gold standard and we have yet to see anything else come close," Okarma said at the BIO CEO conference Monday.
But Benjamin of Rodman & Renshaw doesn't believe reprogramming poses an immediate threat to Geron.
"I think [reprogramming] is very intriguing and has a lot of potential, but it's at a nascent stage that I consider more noise than anything else," said Benjamin.
Mark Gross, a physics professor at California State University who was attending the BIO CEO conference as a potential investor, agreed that reprogramming technology is in too early of a stage to threaten Geron.
"[Reprogramming] is promising, but these things take time and we don't know which path will lead to fruition and which will lead to a dead end," he said.

Monday, February 11, 2008

SOMEONE LEFT ME THIS ON MY EMAIL-INTERESTING

I'M NOT JUDGING ANYONE BUT I BELIEVE EVERYONE HAS SOME SAY WHEN THEY HAVE A TERMINAL ILLNESS. WHAT DO YOU THINK?

Wife's death was mercy killing, husband's family says
by The Oregonian
Wednesday February 06, 2008, 10:55 AM

Friends and family of John Roberts, the Gresham man arrested in the death of his wife, Virginia, say her death Saturday was not a cold-blooded attack but an act of compassion for a woman living with ALS, or Lou Gehrig's Disease.
John Roberts' brother and daughter and a close family friend told The Oregonian that Virginia's ALS had worsened in the weeks leading to her death on Saturday. They say John Roberts hinted to them that Virginia had asked him to help take her life when she no longer wished to carry on.
Friends and family of John Roberts say Virginia Roberts was born in Guatemala. No members of her family could be immediately reached for confirmation of her reported disease.
"There is a story that makes this not just a murder," said Greg Roberts, a former Seattle police detective and John Roberts' brother. "It is my firm belief that this was a pact between the two of them, that she asked him to do this.
"And part of the reason why they chose this method rather than going down the assisted suicide route was that she was so proud that she didn't want to let herself get into the condition she would need to be in before they'd be allowed" to participate in Oregon's Death with Dignity program, which requires a person to be within six months of death.
Police arrested Roberts on an accusation of murder after receiving a 9-1-1 call at 9:44 a.m. Saturday. The caller said he shot someone.
Inside the couple's one-story home at 4160 NE El Camino Drive, police found Virginia Roberts dead from a single gunshot wound to the head. Police are not releasing the recording of the 9-1-1 call. Roberts remains in jail without bail.
Roberts' attorney, Angel Lopez, and Don Rees, a Multnomah County senior deputy district attorney prosecuting the case, declined to comment. Gresham police Capt. Tim Gerkman also declined to discuss specifics of the investigation.
"We're trying to track down all leads and possible motives, or prove or disprove different theories or reasons that this crime was committed," Gerkman said.
A grand jury is scheduled to review the case on Friday. Roberts is scheduled to appear in court Tuesday.
According to the ALS Association, amyotrophic lateral sclerosis is a progressive disease affecting nerve cells in the spinal cord and brain. Those with the disease are eventually robbed of their ability to control muscle movements, leading to paralysis. About 80 percent of those diagnosed with the disease die within five years.
The ALS association estimates that 5,600 each year are diagnosed with the disease and about 30,000 Americans may have the disease at a given time.
-- Brad Schmidt

Saturday, February 9, 2008

THIS SO TRUE

One evening an old Cherokee told his grandson about a battle that goes on inside people. He said, "My son, the battle is between two "wolves" inside us all.
One is Evil. It is anger, envy, jealousy, sorrow, regret, greed, arrogance, self-pity, guilt, resentment, inferiority, lies, false pride, superiority, and ego.
The other is Good. It is joy, peace, love, hope, serenity, humility, kindness, benevolence, empathy, generosity, truth, compassion and faith."
The grandson thought about it for a minute and then asked his grandfather: "Which wolf wins?"
The old Cherokee simply replied, "The one you feed".

Friday, February 8, 2008

RESPONSE TO J.M.C

J.M.C. LEFT A RESPONSE AND A QUESTION TO MY POST ON THE LITHIUM STUDAY:

J.M.C. has left a new comment on your post "SOME INFO ON THAT STUDY (ITALIAN STUDY ON LITHIUM)...":
"We can only hope this does not end the way Myotrophin did. Mixing with Rilutek is interesting but not all PALS agree with that drug nor do they take it. What will be their option"?

TO ANSWER YOUR QUESTION-WHAT OTHER CHOICE DO WE HAVE?? Riluzole BRAND NAME RILUTEK? I WAS TOLD BY MY DOCTOR THAT FIRST, IT REALLY ONLY PROLONGS LIFE FOR 3 MONTHS. IF I'M AT THAT POINT IN MY DISEASE-I WOULD JUST RATHER DIE WITH DIGNITY. I DON'T WANT ANY HEROIC MEASURES TAKEN WHEN I'M AT THAT POINT-THAT IS NO WAY TO LIVE--I HAVE ALREADY SIGNED THE DNR-(DO NOT RECESITATE).
AND SECONDLY, MY DOCTOR ADVISED ME AGAINST TAKING RILUTEK W/ LITHIUM-THE SIDE EFFECTS FAR OUT WEIGH THE POSITIVES. AND I PLAN ON KICKING THIS DISEASE'S ASS ANYWAY I CAN. WE DON'T KNOW ENOUGH ABOUT LITHIUM AND ALS YET AND I'M NOT GOING TO WAIT AROUND FOR THE RESULTS OF A UNITED STATES CLINICAL TRIAL-WE DON'T HAVE THE LUXURY OF TIME-THIS IS SOMETHING POSITIVE IN AN ALS WORLD DOMINATED BY NEGATIVITY.
J.M.C., IT SCARES THE SHIT OUT OF ME TO THINK ABOUT WHAT THE LATTER PART OF THIS DISEASE IS CAPABLE OF.
SO AGAIN, I ASK YOU- WHAT OTHER OPTION DO WE HAVE??????

FINALLY SOME GOOD NEWS-EMBRACE IT.
EMAIL ME AT schemera@yahoo.com
DREW

Thursday, February 7, 2008

SOME INFO ON THAT STUDY (ITALIAN STUDY ON LITHIUM)

THIS IS A SYNOPSIS OF THE ITALIAN STUDY ON LITHIUM

The ALS Association Works with Investigators onFollow Up Study of Lithium for Treating ALS
[Quick Summary: An Italian study of 44 people reports that a 15-month trial found that daily doses of the drug lithium, used to treat bipolar disorder, significantly slowed the progression of ALS in patients also taking riluzole, the only FDA-approved for the treatment of Lou Gehrig’s disease.

The ALS Association is working with investigators and funding organizations to plan a follow up clinical study of lithium as a treatment for ALS.

The 15-month trial conducted on 44 people with amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease, reported that the progressive neurodegenerative disease was slowed significantly in patients receiving daily doses of lithium along with riluzole, the only drug approved by the U.S. Food & Drug Administration for the treatment of ALS.

Francesco Fornai at the University of Pisa (Italy) with colleagues at the University of Novara (Italy) and the Santa Lucia Foundation in Rome, demonstrated that lithium was neuroprotective and increased survival in the mouse model of ALS. These promising results led to the clinical study.
IF WE (PALS-PEOPLE W/ ALS) WAIT AROUND FOR THE GOOD OLD USA TO DO A CLINICAL TRIAL-WELL YOU KNOW.......................
THE FULL REPORT CAN BE FOUND ON:
http://www.alsa.org/research

Wednesday, February 6, 2008

MY CLOUMBIA PRESB. HOSPITAL VISIT AT THE ELEANOR AND LOU GEHRIG CENTER FOR ALS

HEY ALL,

AS YOU MAY OR MAY NOT KNOW-I WENT TO COLUMBIA LAST THURSDAY TO MEET DR. ANDREWS. SHE WAS GREAT--- THOROUGH AND EXTREMELY CURRENT. ANDRA AND I WENT ARMED W/ QUESTIONS ABOUT A LITHIUM STUDY THAT WAS DONE IN ITALY THAT SHOWED OVER A 15 MONTH PERIOD TO BRING ALS TO A STANDSTILL. IN LOW DOSES IT SHOWED THAT THE PROGRESSION OF ALS SLOWED TO A SLOW CRAWL. GREAT NEWS. THE WHITE PAPER IS GOING TO BE PRESENTED APRIL 16TH BUT NEWS HAS SPREAD LIKE WILD FIRE. DR. ANDREWS KNEW ALL ABOUT IT AND SAID IT WAS A REPUTABLE STUDY. SHE ALSO ENCOURAGED ME TO TRY IT-SO I AM IN TWO MORE WEEKS.

I HAVE TO WAIT TILL MY MUSCLE TREMOR AND ANTI-SPASTIC MEDICATION IS TITRATED. MEANING I HAVE TO BUILD UP TO MY REGULAR DOSAGE-3 PILLS A DAY:

IT IS CALLED-BACLOFEN AND IT IS USED IN PATIENTS WHO HAVE MS BUT SINCE I AM STILL REALLY STRONG AND MY MUSCLES SHOW NO SIGN OF ATROPHY, SHE THOUGHT IT WAS A GOOD IDEA. THE REASON BEING-I HAVE BALANCE ISSUES. IT WOULD BE ONE THING IF I'M HAVING BALANCE ISSUES W/ LOSS OF MUSCLE BUT I'M HAVING THE ISSUES WITH MY MUSCLES INTACT. SO, I'M STRONG ENOUGH TO HOLD MYSELF UPRIGHT IF MY MUSCLES DON'T SPASM. OTHERWISE, I WALK LIKE FRANKENSTEIN!! HAHA. HOPING THE BACLOFEN WILL RELAX MY MUSCLES WHEN I WALK. RIGHT NOW IT'S LIKE WALKING WHEN YOUR MAKING A MUSCLE-TRY IT-WALK WHILE YOUR FLEXING YOUR MUSCLES IN YOUR LEG. IT'S HARD. I TAKE IT AT BEDTIME FOR THE FIRST WEEK TO GET MY BODY TO BECOME USED TO IT. AND THE 2ND WEEK-ONE IN THE MORNING AND ONE AT NIGHT AND THEN AT WEEK 3 -MORNING-NOON-AND NIGHT. AND THEN THE LITHIUM. I WILL LET YOU KNOW HOW THAT WORKS OUT.


What is baclofen?
Baclofen is a muscle relaxant and an antispastic agent. The exact way that baclofen works is unknown.
Baclofen is used to relieve the muscle spasms, pain, and muscular rigidity associated with multiple sclerosis.
Baclofen may also be used for purposes other than those listed in this medication


guide.



ENOUGH ABOUT THAT

I'M A PERFECT GINUEA PIG FOR ALMOST EVERY CLINICAL TRIAL THEY HAVE-SO THATS GREAT NEWS. WHATEVER IT TAKES!!!!!!!!

AND I'M TOTALLY HEALTHY FOR SOMEONE WHO HAS MY CHALLANGE. SO GOOD NEWS THERE.

COLUMBIA HAS THE MOST COMPREHENSIVE MULTI-DISCIPINED ALS CLINIC IN THE USA-SO GOOD NEWS THERE TOO.



MORE TO COME..............

THAN YOU AGAIN FOR ALL OF YOUR SUPPORT-YOU PEOPLE ARE TRULY AMAZING!



LOVE YA,

DREW

Sunday, February 3, 2008

A GREAT QUOTE ON THE HEELS OF THE POPE'S STATEMENT AND MY REACTION

Our deepest fear is not that we are inadequate.
Our deepest fear is that we are powerful beyond measure.
It is our Light, not our Darkness, that most frightens us.
We ask ourselves, "Who am I to be brilliant, gorgeous, talented and fabulous?"
Actually, who are you not to be?"
You are a Child of God!

Nelson Mandela, 1994 Inaugural Speech

Saturday, February 2, 2008

A REACTION TO THE POPE

HE'S NOT THE ONE FIGHTING TO LIVE
AND AN ANSWER TO THE QUOTE I HAVE HIGHLIGHTED-I'M NOT DYING A NATURAL DEATH, POPE BENEDICT!! IF YOU WERE IN MY SHOES-YOU WOULD DO ANYTHING TO LIVE. SHATTERING HUMAN DIGNITY WOULD BE GIVING UP. ALTHOUGH I RESPECT ANYONE'S OPINION-I DO NOT HAVE TO AGREE-I'M GOING TO THE POPE'S MASS IN APRIL-TO BE CONTINUED..........

Pope says some science shatters human dignity
By Philip PullellaThu Jan 31, 9:57 AM ET

Pope Benedict said on Thursday that embryonic stem cell research, artificial insemination and the prospect of human cloning had "shattered" human dignity.
In an address to members of the Vatican department on doctrinal matters, Benedict said the Church had a duty to defend the "great values at stake" in the field of bioethics.
The speech was the latest in a series in which the conservative Pope has told his listeners that scientific progress should not be accepted uncritically.
Benedict, who headed the same department for years before his election in 2005, said the Church was not against scientific progress but wanted it based on "ethical-moral principles."
He said this included total respect for the human being as a person "from conception until natural death," and respect for the natural transmission of life through sexual intercourse.
Practices like freezing embryos, suppression of embryos in multiple pregnancies, embryonic stem cell research, the prospect of human cloning and artificial insemination outside the body had "shattered the barriers meant to protect human dignity," he said.
"When human beings in the weakest and most defenseless state of their existence are selected, abandoned, killed or used as pure 'biological material,' how can one deny that they are being treated not as 'someone' but as 'something,"' he said.
Such practices "questioned the very concept of the dignity of man," he said in the speech to the department known as the Congregation for the Doctrine of the Faith.
Widespread interest in medicine by the general public, who get most of their information from the media, had made it even more imperative for the Church to take a stand, he said.
Embryonic stem cell research involves the destruction of embryos. Scientists hope to use stem cells to transform medicine, providing regenerative treatments for injuries and seeking new insights into diseases like cancer and AIDS.
Last year scientists reported they had tricked ordinary skin cells into behaving like embryonic stem cells.
The Pope said the Church "appreciates and encourages" research on stem cells that come from other parts of the body and do not involve embryos or their destruction.
He rejected accusations from critics who say the Church is an obstacle to science and human progress, saying growing concern about cloning and other practices showed it was right to raise the alarm.
It was the Pope's latest foray into scientific issues. On Monday he warned against the "seductive" powers of science, saying it was important that science did not become the sole criteria for goodness.
U.S. Cardinal William Levada, Benedict's successor as head of the doctrinal department, said it was mulling the possibility of preparing a new Vatican document on bioethical issues.
(Editing by Michael Winfrey)



Today, I will remember to face my climb with optimism. Even if my progress sometimes seems slow to me, it's still a long way from where I once was.